Related Experiment Video
Updated: Feb 1, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer
Danyang Han1, Juanjuan Xu2, Cairu Guo2
1The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang Central Hospital, Luoyang, P. R. China. hdy1251698533@163.com.
Abstract:
Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit. Building upon these observations, this study evaluated the potential synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor and examined the mechanistic basis for their interaction in breast cancer. Notably, we found that this regimen could significantly suppress the proliferation, migration, and invasion of MCF-7 and MDA-MB-231 cells, and promote cell apoptosis. In addition, the levels of p-ERK, NF-κB, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.
Insights
Combining apatinib with PD-L1 inhibitors shows synergistic antitumor effects in breast cancer models. This combination significantly suppresses cancer cell growth and promotes apoptosis, supporting potential clinical applications.
Area of Science:
- Oncology
- Cancer Research
- Immunotherapy
Background:
- Apatinib demonstrates antiangiogenic and antitumor properties in breast cancer.
- Programmed death-ligand 1 (PD-L1) inhibitors have shown clinical efficacy.
- Investigating combination therapies is crucial for improving breast cancer treatment outcomes.
Purpose of the Study:
- To evaluate the synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor in breast cancer.
- To explore the mechanistic basis of this drug combination's interaction.
- To assess the potential clinical utility of this combined therapeutic approach.
Main Methods:
- In vitro studies using MCF-7 and MDA-MB-231 breast cancer cell lines.
- Assessment of cell proliferation, migration, invasion, and apoptosis.
- Analysis of key signaling pathway markers including p-ERK, NF-κB, and Slug.
Main Results:
- The combination of apatinib and PD-L1 inhibitor significantly suppressed breast cancer cell proliferation, migration, and invasion.
- Enhanced apoptosis was observed in treated cancer cells.
- In vitro mechanistic studies revealed reduced levels of p-ERK, NF-κB, and Slug.
Conclusions:
- The combination of apatinib and PD-L1 inhibition exhibits significant synergistic antitumor effects in breast cancer.
- Consistent in vitro and in vivo synergy supports the clinical potential of this combination therapy.
- Targeting these pathways may offer a novel therapeutic strategy for breast cancer treatment.
More Related Videos
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
00:46Feedback Inhibition
01:26PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
02:19Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
01:07Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
01:30Enzyme Inhibition
01:24Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...